
Medical conditions associated with significantly higher rate of active Bornavirus infection are acute depressive episodes (uni- and bipolar), in 80-90% of patients, chronic obsessive-compulsive disorders (OCD), in at least 50-60% of patients, and chronic fatigue syndrome (CFS/ME0 in at least 40% of patients. [6] The symptoms that are common to the majority of these patients are cognitive deficits and bradylogia (abnormally slow speech), reduced intellectual capability, attention and concentration deficits (especially among young adults and children), memory loss, and learning disabilities (especially among children and young adults). [6]
...........Treatment
Patients diagnosed with BDV infection are treated with a drug that has been approved for the past 40 years for treatment of influenza A virus, which has the active ingredient of amantadine sulphate. [6] This has shown to be highly effective against natural Bornaviruses. Amantadine sulphate is a virostatic agent that inhibits virus replication, and, therefore, prevents the formation of harmful viral proteins. [6] Around 70-80% of patients infected with acute depression derive long-term benefits from amantadine sulphate, and it could be prescribed with antidepressants as well. [6]
Dosage level should be 2-4 mg of amantadine sulphate per day per kg of body weight. A patient who weighs 75 kg should take 150-300 mg of amantadine sulphate daily, and the initial dose of 1 mg of amantadine sulphate per kg of body weight for the first three or four days should be observed. [6]
Treatment duration should normally last up to 3 months, and clinical improvement are to be expected in the first month. During the first week, some restlessness and sleep disturbances are possible. [6]
Some studies have also found Ara-C (1-beta-arabinofuranosylcytosine) a drug often used in chemotherapy, to be effective in inhibiting the replication and spread of BDV. [2]